MicroAlgo (NASDAQ:MLGO) Azioni

MicroAlgo

MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.

MicroAlgo Inc

CBL &amp; Associates (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBL#NYSE">CBL</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.16 by 50 percent. This is a 42.86 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $140.905 million which beat the analyst consensus estimate of $134.000 million by 5.15 percent. This is a 8.67 percent increase over sales of $129.665 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

CBL & Associates Q2 EPS $0.08 Misses $0.16 Estimate, Sales $140.905M Beat $134.000M Estimate

WIIM

Centrus Energy shares are trading higher after the company reported better-than-expected Q2 financial results.

As of Aug. 6, 2025, two stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Resideo Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REZI#NYSE">REZI</a>)</h3>
<ul class="wp-block-list">
<li>On Aug. 5, Resideo Technologies reported better-than-expected second-quarter financial results and raised its FY25 guidance. &#8220;Resideo had an exceptional second quarter, reporting record high results that were above the high-end of the range for all our key financial metrics. We are pleased to report that both the ADI and Products and Solutions segments generated organic net revenue growth, gross margin expansion, and robust Adjusted EBITDA growth,&#8221; said Jay Geldmacher, Resideo&#8217;s President and CEO. The company's stock jumped around 12% over the past month and has a 52-week high of $29.40.</li>
<li>RSI Value: 70.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>REZI Price Action: Shares of Resideo Technologies gained 1.8% to close at $26.23 on Tuesday.</li>
<li>Edge Stock Ratings: 79.46 Momentum score with Value at 28.96. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/rezi"><img loading="lazy" decoding="async" width="447" height="180" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06073930/image-93.png" alt="" class="wp-image-1016774" style="width:345px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06073930/image-93.png 447w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06073930/image-93-300x121.png 300w" sizes="(max-width: 447px) 100vw, 447px" /></a></figure>
<h3 class="wp-block-heading">Aecom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>)</h3>
<ul class="wp-block-list">
<li>On Aug. 4, AECOM reported better-than-expected quarterly adjusted EPS results and raised both its FY25 GAAP EPS and adjusted EPS guidance. &#8220;The strength of our third quarter results, which included outperformance on all key financial metrics, demonstrated the benefits of our competitive edge platform and the high returns we earn on our growth investments,&#8221; said Troy Rudd, AECOM&#8217;s chairman and chief executive officer. The company's stock gained around 10% over the past six months <a href="https://www.benzinga.com/quote/ACM">has a 52-week high</a> of $121.73.</li>
<li>RSI Value: 76.7</li>
<li>ACM Price Action: Shares of Aecom gained 6.3% to close at $119.00 on Tuesday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/08/46856530/top-2-health-care-stocks-you-may-want-to-dump-in-q3">Top 2 Health Care Stocks You May Want To Dump In Q3</a></li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

JOBY

REZI

Top 2 Industrials Stocks That May Plunge In August

Parsons shares are trading lower after the company reported worse-than-expected Q2 revenue results.

William Blair analyst Ross Sparenblek upgrades JBT Marel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBTM#NYSE">JBTM</a>) from Market Perform to Outperform.

Upgrades

Analyst Ratings

JBTM

William Blair Upgrades JBT Marel to Outperform

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst Maria Ripps downgraded the rating for Vivid Seats Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) from Buy to Hold and lowered the price target from $80 to $23. Vivid Seats shares closed at $1.02 on Tuesday. <a href="https://www.benzinga.com/quote/SEAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Jeffrey Hammond downgraded the rating for Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) from Overweight to Sector Weight. Atkore shares closed at $56.39 on Tuesday. <a href="https://www.benzinga.com/quote/ATKR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Paul Newsome downgraded Kemper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMPR#NYSE">KMPR</a>) from Overweight to Underweight and lowered the price target from $75 to $50. Kemper shares closed at $61.49 on Tuesday. <a href="https://www.benzinga.com/quote/KMPR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Sheila Kahyaoglu downgraded the rating for CACI International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) from Buy to Hold and lowered the price target from $570 to $535 CACI International shares closed at $471.53 on Tuesday. <a href="https://www.benzinga.com/quote/CACI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Timothy Zhao downgraded New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) from Buy to Neutral and slashed the price target from $58 to $50. New Oriental Education shares closed at $46.62 on Tuesday. <a href="https://www.benzinga.com/quote/EDU/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CACI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="553" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06081710/image-100-1024x553.png" alt="" class="wp-image-1016866" style="width:626px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06081710/image-100-1024x553.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06081710/image-100-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06081710/image-100-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/06081710/image-100.png 1136w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/08/46856530/top-2-health-care-stocks-you-may-want-to-dump-in-q3">Top 2 Health Care Stocks You May Want To Dump In Q3</a></li>
</ul>
Photo via Shutterstock

Downgrades

ATKR

CACI

New Oriental Education & Technology Group

KMPR

SEAT

This CACI International Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

<ul>
<li>VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMS</li>
<li>Amifampridine may be considered as a supportive care treatment</li>
<li>Guideline inclusion may raise clinical awareness of cancer-associated LEMS to support broader VGCC diagnostic testing and treatment adoption &nbsp;</li>
</ul>
CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the National Comprehensive Cancer Network&#xAE; (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines&#xAE;) for Small Cell Lung Cancer (SCLC) now include new additions involving Lambert Eaton myasthenic syndrome (LEMS), amifampridine (FIRDAPSE&#xAE;), and the tests for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies.
The updated NCCN Clinical Practice Guidelines in Oncology for SCLC relating to LEMS now include symptom specificity—characterized by proximal muscle weakness and autonomic dysfunction. Under "Signs and Symptoms of Small Cell Lung Cancer" (SCL-A 2 of 2), the guidelines recommend diagnosis through a neurological evaluation, ideally in consultation with a neurologist, which may include testing for PQ- and N-type VGCC antibodies. Additionally, under "Principles of Supportive Care" (SCL-D), the guidelines recommend that amifampridine should be considered as a treatment in consultation with neurology.1
Approximately 50 percent of LEMS cases are associated with an underlying malignancy, most commonly SCLC. Literature suggests that LEMS is observed in 3 percent of SCLC patients. Based on an internal healthcare database analysis of SCLC claims, potentially 90 percent of LEMS patients with SCLC went undiagnosed. These undiagnosed LEMS patients may suffer from LEMS symptoms while undergoing treatment for SCLC.

Biotech

General

CPRX

Catalyst Pharmaceuticals Applauds NCCN Guideline Update Adding LEMS Diagnosis And Amifampridine Support For SCLC Patients

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Holdings To Acquire ~30% Of Outstanding Shares Of MarushoHotta, Terms Not Disclosed

-- Up to $32 Million in Upfront and Milestone Payments, Plus Royalties --
-- Kaken Expertise in Commercializing Innovative Therapies Supports Navenibart's Potential to be First-Choice HAE Treatment in Japan --
-- Updated Cash Runway Supports the Company's Operating Plan Into 2028 --
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.astriatx.com&amp;esheet=54303627&amp;newsitemid=20250806414306&amp;lan=en-US&amp;anchor=Astria+Therapeutics%2C+Inc.&amp;index=1&amp;md5=0e664f468f28946e245fb15b2d2b278b">Astria Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it has exclusively licensed development and commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd., a Japanese specialty pharmaceutical company, for navenibart, a long-acting investigational monoclonal antibody inhibitor of plasma kallikrein, in Phase 3 development for the preventative treatment of hereditary angioedema (HAE). Under the agreement, Astria will receive an upfront payment of $16 million, with the potential for an additional $16 million in total commercialization and sales milestones. In addition to these payments, Astria is also eligible for tiered royalties with the royalty rate as a percentage of net sales up to 30%, and partial Phase 3 cost reimbursement.
Kaken will also provide support for the ALPHA-ORBIT Phase 3 trial in Japan, be responsible for regulatory submissions in Japan, and will reimburse Astria for a portion of the costs of the navenibart Phase 3 program.
Including the upfront payment from Kaken and the expected reimbursement by Kaken of a portion of the Company's Phase 3 program costs, the Company expects that its cash, cash equivalents and short-term investments will be sufficient to fund its current operating plan into 2028.

ATXS

Astria Therapeutics Licenses D&C Rights In Japan To Kaken Pharma For Navenibart In Phase 3 Development For Preventative Treatment Of HAE; Astria To Receive $16M Upfront, With Potential For $16M In Commercialization Milestones

NielsenIQ (NIQ) a leading consumer intelligence, company, today announced the acquisition of Mtrix, a leading Brazilian SaaS company that delivers end-to-end visibility across the indirect distribution supply chain. This is the latest of nine tuck-in acquisitions NIQ has made to further enhance its analytics capabilities and retailer tools and strengthen its position as a leading consumer intelligence company, including its recent acquisition of sensory insights platform Gastrograph AI and combination with GfK in 2023.
This acquisition also marks NIQ's first additive transaction in Latin America since becoming part of Advent International's portfolio in 2021 and underscores NIQ's long-term commitment to the region.
Mtrix's platform integrates data between manufacturers, wholesalers, and distributors, providing real-time insights into stock levels, sell-in, and sell-out activity. With over a decade of experience, Mtrix supports more than 2,000 distributor and wholesaler partners, capturing transactions from over 1.2 million points of sale across Brazil. Its client base includes nearly 100 of the largest CPG manufacturers in the region.

Nuveenn Intermediate Duration Quality Municipal Term Fund Common Shares of Beneficial Interest

NielsenIQ Announces Acquisition Of Mtrix, A Brazilian SaaS Company That Delivers End-To-End Visibility Across The Indirect Distribution Supply Chain; Terms Not Disclosed

AVS Bio Acquires ImmunoPrecise Antibodies (Europe) To Expand Its European Footprint And Add Capabilities In Antibody Discovery, Protein Expression And Organoi Growth Factor Development And Manufacturing To Portfolio

Six Flags Entertainment shares are trading lower after the company reported worse-than-expected Q2 sales results.

<ul>
<li>ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3</li>
<li>ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in patients with chronic hepatitis delta</li>
</ul>
Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company's registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated. ECLIPSE 3 is a Phase 2b trial designed to compare the combination of tobevibart and elebsiran to bulevirtide treatment in patients with CHD. ECLIPSE 3 will provide important supportive data to help establish access and reimbursement in key markets.

Vir Biotechnology Launches Final ECLIPSE Trial, Advancing Full Registrational Program For Chronic Hepatitis Delta

Oppenheimer analyst Ian Zaffino maintains Frontdoor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) with a Outperform and raises the price target from $56 to $63.

Price Target

FTDR

Oppenheimer Maintains Outperform on Frontdoor, Raises Price Target to $63

TRMB

Trimble shares are trading higher after the company reported better-than-expected Q2 financial results, issued Q3 sales guidance above estimates, and raised its FY25 guidance.

USEA

United Maritime Q2 Adj. EPS $0.02 Beats $(0.14) Estimate, Sales $12.473M Beat $10.700M Estimate

Needham analyst James Ricchiuti maintains Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) with a Buy and raises the price target from $135 to $155.

AEIS

Needham Maintains Buy on Advanced Energy Indus, Raises Price Target to $155

UBS analyst Joshua Chan downgrades Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) from Buy to Neutral and lowers the price target from $480 to $270.

UBS Downgrades Gartner to Neutral, Lowers Price Target to $270

Pulmatrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PULM#NASDAQ">PULM</a>) reported quarterly losses of $(0.42) per share. This is a 73.58 percent increase over losses of $(1.59) per share from the same period last year.

PULM

Pulmatrix Q2 EPS $(0.42) Up From $(1.59) YoY

Oppenheimer analyst Ian Zaffino maintains Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) with a Outperform and raises the price target from $215 to $240.

Oppenheimer Maintains Outperform on Enpro, Raises Price Target to $240

Press Releases

MicroAlgo Inc. Develops Quantum Convolutional Neural Network (QCNN) Architecture to Enhance the Performance of Traditional Computer Vision Tasks Using Quantum Mechanics Principles

MicroAlgo Inc. Develops Blockchain-Based Traceable IP Rights Protection Algorithm

MicroAlgo Inc. Announces Research on Quantum Information Recursive Optimization (QIRO) Algorithm, for Combinatorial Optimization Problems to Expand and Solve New Ideas

MicroAlgo Inc. Announces a Quantum Entanglement-Based Novel Training Algorithm — Entanglement-Assisted Training Algorithm for Supervised Quantum Classifiers

MicroAlgo Inc. Researches Quantum Machine Learning Algorithms to Accelerate Machine Learning Tasks

Navitas (NASDAQ: NVTS) Surges on NVIDIA Deal – SNYR, VIGL, XAGE Lead $2 Stock Watch Now, More Inside

MicroAlgo Inc. Explores Optimization of Quantum Error Correction Algorithms to Enhance Quantum Algorithm Accuracy

MicroAlgo Inc. Adopts Quantum Phase Estimation (QPE) Method to Enhance Quantum Neural Network Training

MicroAlgo Inc. Integrates Quantum Image LSQb Algorithm with Quantum Encryption Technology to Build a More Secure Quantum Information Hiding and Transmission System

MicroAlgo Inc. Announces the Development of Grover-based Quantum Algorithm Technology for Finding Pure Nash Equilibria in Graphical Games

MLGO

NVDA

NVTS

PRSO

SNYR

VIGL

XAGE

Accenture plc Class A Ordinary Shares (Ireland)

Accenture

ASGN

Alpha Technology Group Limited - Class A Ordinary Shares

Alpha Technology Group

BigBear.ai Hldgs

CI&T

Castellum

Cognizant Technology Solutions Corporation - Class A Common Stock

Cognizant Tech Solns

Endava plc American Depositary Shares (each representing one Class A Ordinary Share)

Comments

MicroAlgo

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO